PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-23.20%
Negative net income growth while Biotechnology median is 0.00%. Seth Klarman would suspect a firm-specific problem if peers maintain profit growth.
3.49%
D&A growth of 3.49% while Biotechnology median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
-100.00%
Deferred tax shrinks yoy while Biotechnology median is 0.00%. Seth Klarman would see potential advantage if actual tax outflows do not spike.
19.58%
SBC growth of 19.58% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or staff additions causing more equity grants.
19.36%
A slight increase while Biotechnology median is negative at -8.71%. Peter Lynch might see peers reaping more free cash if they can do so without impacting sales.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
55.56%
AP growth of 55.56% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or credit policies affecting the difference.
-124.52%
Other WC usage shrinks yoy while Biotechnology median is 0.00%. Seth Klarman would see an advantage if top-line is stable or growing.
56.31%
Growth of 56.31% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or one-off revaluations explaining the difference.
-16.84%
Negative CFO growth while Biotechnology median is 0.00%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.
100.00%
CapEx growth of 100.00% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or upgrades behind the difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Investing flow of 100.00% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or deals prompting that difference.
-594.74%
Debt repayment yoy declines while Biotechnology median is 0.00%. Seth Klarman fears increased leverage if expansions do not yield quick returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.